HD-OPM Archive
Topics › Lp(a)

Tsimikas: Lp(a) risk can be managed with LDL under 65 and tight risk-factor control

Louis Nervegna · Nov 10, 2026 · ♥ 13 reactions · 1 comments · original Facebook post
Lp(a)LDL, ApoB & lipid panelPCSK9, ezetimibe & newer drugs
AI summary & key facts

Louis quotes Sam Tsimikas, who calls Lp(a)HORIZON a success because it suggests Lp(a) risk can be reduced by keeping LDL-C at or below 65, blood pressure at 120 or lower, controlling other risk factors and taking proven medicines. In his Lp(a) clinic about 75% take a statin, 50% ezetimibe, 50% a PCSK9 inhibitor, plus aspirin.

Quoted from Sam Tsimikas, one of the world’s foremost clinical experts on Lp(a):

“I do not see Lp(a)HORIZON as a failure…
I see it as a MAJOR SUCCESS for our patients. Why? Because we learned that there may be an alternative to reduce Lp(a) mediated risk, which is to:

a) keep LDL-C below 65 or lower;
b) keep blood pressure at 120 or lower;
c) control all other risk factors as best as possible;
d) take your medicines that have proven efficacy regularly.”

“Lp(a)HORIZON has now armed us with actionable (and inexpensive) knowledge to help people with elevated Lp(a). Take a big breath and sigh of relief, Lp(a) risk can be managed. Treat it like you do other risk factors and your prognosis will be good, like many of my Lp(a) Clinic patients.”

“In my Lp(a) Clinic, this is my summary of how I treat my patients: 75% on statin, 50% of ezetimibe and 50% (!!) on PCSK9, along with judicious use of aspirin in primary prevention and universal use in secondary prevention. This double/ triple/quadruple combo is highly effective.”

————-

Tsimikas then goes on to explain why he thinks the HORIZON trial failed. There are lots of nuggets of insight in what he says here. His comments about neutralizing the harmful oxidized phospholipids (OxPL) carried by Lp(a) particles seem particularly important.

I took these images from a post by Vital Human- Dr. Daniel Chong, which can be found here: facebook.com/share/p/1E8seSXTF5.

#tsimikasHD #lpaHD #horizonHD #pelacarsenHD #oxplHD

Research cited

← newer: Atorvastatin may 'disarm' Lp(a) by blocking oxidation, a theolder: MESA: CAC under 100, hsCRP under 2 and low visceral fat may →